Intentar ORO - Gratis
Making AI work for you
Business Standard
|October 22, 2025
Technological breakthroughs don't always live up to the hype.
A decade ago, we were told that 3D printing will replace manufacturing of many types of products. A company even demonstrated building a house using a 3D printer. But we are still buying and using products made in factories. Yes, 3D printers have become more and more affordable and in consumer products marketing most designers use 3D printers to create prototypes, instead of wood or plastic moulds.
Virtual reality and artificial reality, too, seem to have not grown the way they were supposed to take over our real world. IoT, or internet of things, has had a slow start but we are seeing more of it everywhere. I was impressed that a B School in Mumbai is using this technology to issue books to students. But has it taken over our world? Have refrigerators started ordering for milk, bread and eggs, as they were supposed to? No, not yet.
In contrast AI, especially generative AI, has had a great start. And a lot of it is not just hype. ChatGPT, from its late 2022 launch, now boasts of more than 700 million worldwide users. In India, too, ChatGPT has had a great beginning.
So have all the other GenAI platforms like Gemini, Perplexity, CoPilot, Claude and others.
There is widespread fear that ChatGPT and its ilk will replace humans causing widespread job losses.
Esta historia es de la edición October 22, 2025 de Business Standard.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Business Standard
Business Standard
Nalco urges Odisha govt to expedite land handover process for ‘30K cr projects
Navratna central public-sector enterprise (CPSE) Nalco has requested the Odisha government to expedite the land handover process for its 30,000 crore expansion projects that will boost capacity and help it achieve the Maharatna status by 2030.
1 mins
March 10, 2026
Business Standard
Women-led startups saw 9% funding drop in 2025
Female labour participation just 42%, among lowest in G20: Axis Bank study
3 mins
March 10, 2026
Business Standard
How India can kick the West Asian oil habit
Increasing the use of alternative fuels like ethanol could be one way out
6 mins
March 10, 2026
Business Standard
India’s T20 WC win brings new stars to brand crease
\"Sachin Tendulkar carried Indian cricket on his shoulders for 21 years.
3 mins
March 10, 2026
Business Standard
UBS downgrades OMCs as oil crosses $100/bbl
The recent rally in crude prices and refining margins create a sense of déjà vu, UBS said, mirroring the 2022 oil market disruption.
1 min
March 10, 2026
Business Standard
LIC drove 18% rise in life insurers’ NBP in Feb
New business premium of life insurance companies grew 18 per cent year-on-year (Y-o-Y) to ₹35,417 crore in February, driven by robust growth at the state-owned Life Insurance Corporation of India (LIC) due to a favourable base.
1 mins
March 10, 2026
Business Standard
Why India needs Russian oil
India's oil security is becoming increasingly fragile. Over 80 per cent of its crude imports come from just two suppliers — West Asia and Russia — both now facing geopolitical stress. In this environment, resuming full purchases of Russian oil may not be a choice but a necessity. Here are eight reasons why.
3 mins
March 10, 2026
Business Standard
India, Uzbekistan launch pharma-nutra corridor
India and Uzbekistan on Monday launched a structured pharmaceutical and nutraceutical trade corridor aimed at expanding access to the Commonwealth of Independent States (CIS) and the wider Eurasian healthcare market, estimated at $7-10 billion.
1 min
March 10, 2026
Business Standard
A clear derating
Markets risk underperformance if we don’t regain our growth credentials
5 mins
March 10, 2026
Business Standard
Delhi HC allows Dr Reddy’s to make semaglutide for export
A division Bench of the Delhi High Court on Monday affirmed a single-judge Bench’s order allowing pharmaceutical company Dr Reddy’s Laboratories to manufacture the diabetes and weight-management drug semaglutide in India for export to jurisdictions where Danish drugmaker Novo Nordisk does not have patent protection.
2 mins
March 10, 2026
Listen
Translate
Change font size
